{"filing":{"accession_number":"0000313143-26-000057","cik":"0000313143","ticker":"HAE","company_name":"HAEMONETICS CORP","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"hae-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000057/hae-20260605.htm"},"events":[{"id":3649,"run_id":3202,"accession_number":"0000313143-26-000057","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Haemonetics announced a material restructuring of its reportable segment structure, combining Plasma and Blood Center into a single \"Apheresis\" segment and renaming Hospital to \"MedSurg,\" effective Q1 FY2027. This change affects how investors will receive and analyze financial information going forward, including recast historical data and guidance. While segment reorganizations are administrative in nature, this disclosure materially impacts the transparency and comparability of financial reporting, making it material to investors' assessment of the company's business performance and structure.","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-06-05","items":[{"id":4644,"accession_number":"0000313143-26-000057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Haemonetics announced a material restructuring of its reportable segment structure, combining Plasma and Blood Center into a single \"Apheresis\" segment and renaming Hospital to \"MedSurg,\" effective Q1 FY2027. This change affects how investors will receive and analyze financial information going forward, including recast historical data and guidance. While segment reorganizations are administrative in nature, this disclosure materially impacts the transparency and comparability of financial reporting, making it material to investors' assessment of the company's business performance and structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:48:54.606939+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4644,"accession_number":"0000313143-26-000057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Haemonetics announced a material restructuring of its reportable segment structure, combining Plasma and Blood Center into a single \"Apheresis\" segment and renaming Hospital to \"MedSurg,\" effective Q1 FY2027. This change affects how investors will receive and analyze financial information going forward, including recast historical data and guidance. While segment reorganizations are administrative in nature, this disclosure materially impacts the transparency and comparability of financial reporting, making it material to investors' assessment of the company's business performance and structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:48:54.606939+00:00","company_name":"HAEMONETICS CORP","ticker":"HAE","filing_date":"2026-06-05"}]}